{"protocolSection":{"identificationModule":{"nctId":"NCT00221390","orgStudyIdInfo":{"id":"HS#2003-3096"},"organization":{"fullName":"University of California, Irvine","class":"OTHER"},"briefTitle":"Trial of Ropinirole in Motor Recovery After Stroke","officialTitle":"Randomized, Placebo-controlled, Double-blind Pilot Trial to Evaluate the Safety and Efficacy of Ropinirole in Motor Recovery After Stroke"},"statusModule":{"statusVerifiedDate":"2016-10","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2003-10"},"primaryCompletionDateStruct":{"date":"2007-02","type":"ACTUAL"},"completionDateStruct":{"date":"2007-05","type":"ACTUAL"},"studyFirstSubmitDate":"2005-09-19","studyFirstSubmitQcDate":"2005-09-19","studyFirstPostDateStruct":{"date":"2005-09-22","type":"ESTIMATED"},"lastUpdateSubmitDate":"2016-10-28","lastUpdatePostDateStruct":{"date":"2016-11-01","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Steven C. Cramer, MD","investigatorTitle":"Professor","investigatorAffiliation":"University of California, Irvine"},"leadSponsor":{"name":"University of California, Irvine","class":"OTHER"},"collaborators":[{"name":"GlaxoSmithKline","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"The purpose of this study is to assess efficacy, as well as safety, of Ropinirole in improving movement among patients with chronic stroke.","detailedDescription":"Stroke is a leading cause of disability. Current treatments target injury and must be delivered within hours. A body of literature suggests that there are processes ongoing days-months after stroke that can be targeted therapeutically, and improve function. The current study evaluates one such potential therapy, the dopamine agonist ropinirole. The current study tests the hypothesis that patients with chronic stroke randomized to ropinirole+physiotherapy will show improved gait velocity over the 12 weeks of study participation as compared to patients randomized to placebo+physiotherapy. A secondary aim is to test the hypothesis that ropinirole will improve three secondary endpoints at 12 weeks after study entry: the proportion of patients with no significant disability (Barthel Index â‰¥ 95); overall motor status, measured with the arm/leg FM score; and overall physical function, defined as the score on the Stroke Impact Scale-16 (SIS-16). This study will also evaluate the safety of ropinirole in patients recovering from stroke."},"conditionsModule":{"conditions":["Cerebrovascular Accident","Hemiparesis"],"keywords":["stroke","Chronic stroke with hemiparesis"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":52,"type":"ESTIMATED"}},"armsInterventionsModule":{"interventions":[{"type":"DRUG","name":"Ropinirole (+ physical therapy)"},{"type":"DRUG","name":"(vs.) Placebo + physical therapy"}]},"outcomesModule":{"secondaryOutcomes":[{"measure":"Barthel Index","timeFrame":"Measured at weeks 1, 9, and 12"},{"measure":"Leg motor Fugl-Meyer scale","timeFrame":"Measured at baseline and weeks 1, 2, 4, 6, 7, 8, 9, and 12"},{"measure":"Stroke Impact Scale-16","timeFrame":"Measured at weeks 1, 4, 7, 9, and 12"},{"measure":"Gait endurance","timeFrame":"Measured at weeks 1, 2, 4, 6, 7, 8, 9, and 12"},{"measure":"Hamilton Depression Scale","timeFrame":"Measured at baseline and weeks 1, 2, 9, and 12"},{"measure":"Safety","timeFrame":"12 weeks"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Stroke onset 4 weeks-12 months prior\n2. Stroke is radiologically confirmed as either (a) ischemic or (b) hemorrhagic\n3. Minimum age 18\n4. No significant pre-stroke disability\n5. No other stroke in previous 3 months\n6. Absence of major depression\n7. Fugl-Meyer (FM) motor score of 23-83 out of 100\n8. Functional Independence Measure (FIM) ambulation-subscore of 3 or more, and 50 foot walk takes longer than 15 seconds\n\nExclusion Criteria:\n\n1. Significant daytime somnolence or any substantial decrease in alertness, language reception, or attention\n2. Pregnant or lactating\n3. Advanced liver, kidney, cardiac, or pulmonary disease\n4. Orthostatic hypotension\n5. Current use of ciprofloxacin, a centrally acting dopamine agonist, or a centrally active dopamine antagonist\n6. A terminal medical diagnosis consistent with survival \\< 1 year\n7. Coexistent major neurological disease\n8. Coexistent major psychiatric disease\n9. A history of significant alcohol or drug abuse in the prior 3 years\n10. A coexistent disease characterized by an abnormality of CNS dopaminergic tone\n11. Current enrollment in another investigational study related to stroke or stroke recovery\n12. Contraindication to ropinirole prescription","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Steven C Cramer, MD","affiliation":"University of California, Irvine","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"University of California, Irvine Medical Center","city":"Orange","state":"California","zip":"92868","country":"United States","geoPoint":{"lat":33.78779,"lon":-117.85311}}]},"referencesModule":{"references":[{"type":"BACKGROUND","citation":"Gresham GE, Duncan PW, Stason WB, Adams HP, Adelman AM, Alexander DN, Bishop DS, Diller L, Donaldson NE, Granger CV, Holland AL, Kelly-Hayes M, McDowell FH, Myers L, Phipps MA, Roth EJ, Siebens HC, Tarvin GA, Trombly CA. Post-Stroke Rehabilitation. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service, Agency for Health Care Policy and Research, 1995."},{"pmid":"12411667","type":"BACKGROUND","citation":"Rathore SS, Hinn AR, Cooper LS, Tyroler HA, Rosamond WD. Characterization of incident stroke signs and symptoms: findings from the atherosclerosis risk in communities study. Stroke. 2002 Nov;33(11):2718-21. doi: 10.1161/01.str.0000035286.87503.31."},{"type":"BACKGROUND","citation":"Dobkin BH. Neurologic Rehabilitation. Philadelphia: FA Davis, 1996"},{"pmid":"10607636","type":"BACKGROUND","citation":"Nudo RJ. Recovery after damage to motor cortical areas. Curr Opin Neurobiol. 1999 Dec;9(6):740-7. doi: 10.1016/s0959-4388(99)00027-6."},{"pmid":"10838596","type":"BACKGROUND","citation":"Cramer SC, Chopp M. Recovery recapitulates ontogeny. Trends Neurosci. 2000 Jun;23(6):265-71. doi: 10.1016/s0166-2236(00)01562-9."},{"pmid":"2412650","type":"BACKGROUND","citation":"Finklestein S, Campbell A, Baldessarini RJ, Moya KL, Haber SN. Late changes in cerebral monoamine metabolism following focal ventrolateral cerebrocortical lesions in rats. Brain Res. 1985 Oct 7;344(2):205-10. doi: 10.1016/0006-8993(85)90796-6."},{"pmid":"6193832","type":"BACKGROUND","citation":"Finklestein S, Campbell A, Stoll AL, Baldessarini RJ, Stinus L, Paskevitch PA, Domesick VB. Changes in cortical and subcortical levels of monoamines and their metabolites following unilateral ventrolateral cortical lesions in the rat. Brain Res. 1983 Jul 25;271(2):279-88. doi: 10.1016/0006-8993(83)90290-1."},{"pmid":"4018214","type":"BACKGROUND","citation":"Boyeson MG, Feeney DM. Striatal dopamine after cortical injury. Exp Neurol. 1985 Aug;89(2):479-83. doi: 10.1016/0014-4886(85)90107-4."},{"pmid":"9804653","type":"BACKGROUND","citation":"Stroemer RP, Kent TA, Hulsebosch CE. Enhanced neocortical neural sprouting, synaptogenesis, and behavioral recovery with D-amphetamine therapy after neocortical infarction in rats. Stroke. 1998 Nov;29(11):2381-93; discussion 2393-5. doi: 10.1161/01.str.29.11.2381."},{"pmid":"9412643","type":"BACKGROUND","citation":"Cramer SC, Nelles G, Benson RR, Kaplan JD, Parker RA, Kwong KK, Kennedy DN, Finklestein SP, Rosen BR. A functional MRI study of subjects recovered from hemiparetic stroke. Stroke. 1997 Dec;28(12):2518-27. doi: 10.1161/01.str.28.12.2518."},{"pmid":"7100929","type":"BACKGROUND","citation":"Feeney DM, Gonzalez A, Law WA. Amphetamine, haloperidol, and experience interact to affect rate of recovery after motor cortex injury. Science. 1982 Aug 27;217(4562):855-7. doi: 10.1126/science.7100929."},{"pmid":"10830340","type":"BACKGROUND","citation":"Gladstone DJ, Black SE. Enhancing recovery after stroke with noradrenergic pharmacotherapy: a new frontier? Can J Neurol Sci. 2000 May;27(2):97-105."},{"type":"BACKGROUND","citation":"Goldstein LB. Potential impact of drugs on poststroke motor recovery. In: L. B. Goldstein, ed. Restorative Neurology. Advances in pharmacotherapy for recovery after stroke. Armonk, NY: Futura Publishing Co., 1998:241-256."},{"pmid":"11564483","type":"BACKGROUND","citation":"Scheidtmann K, Fries W, Muller F, Koenig E. Effect of levodopa in combination with physiotherapy on functional motor recovery after stroke: a prospective, randomised, double-blind study. Lancet. 2001 Sep 8;358(9284):787-90. doi: 10.1016/S0140-6736(01)05966-9."},{"pmid":"11994808","type":"BACKGROUND","citation":"Sullivan KJ, Knowlton BJ, Dobkin BH. Step training with body weight support: effect of treadmill speed and practice paradigms on poststroke locomotor recovery. Arch Phys Med Rehabil. 2002 May;83(5):683-91. doi: 10.1053/apmr.2002.32488."},{"type":"BACKGROUND","citation":"Richards C, Malouin F, Dumas F, Tardif D. Gait velocity as an outcome measure of locomotor recovery after stroke. In: C. R and O. C, eds. Gait Analysis: Theory and Application. St. Louis: Mosby, 1995:355-364."},{"pmid":"7487453","type":"BACKGROUND","citation":"Potter JM, Evans AL, Duncan G. Gait speed and activities of daily living function in geriatric patients. Arch Phys Med Rehabil. 1995 Nov;76(11):997-9. doi: 10.1016/s0003-9993(95)81036-6."},{"pmid":"12126656","type":"BACKGROUND","citation":"Nieoullon A. Dopamine and the regulation of cognition and attention. Prog Neurobiol. 2002 May;67(1):53-83. doi: 10.1016/s0301-0082(02)00011-4."},{"pmid":"12007669","type":"BACKGROUND","citation":"Medico M, De Vivo S, Tomasello C, Grech M, Nicosia A, Castorina M, D'Agata MA, Rampello L, Lempereur L, Drago F. Behavioral and neurochemical effects of dopaminergic drugs in models of brain injury. Eur Neuropsychopharmacol. 2002 Jun;12(3):187-94. doi: 10.1016/s0924-977x(02)00010-x."},{"pmid":"2914151","type":"BACKGROUND","citation":"Bracha HS, Lyden PD, Khansarinia S. Delayed emergence of striatal dopaminergic hyperactivity after anterolateral ischemic cortical lesions in humans; evidence from turning behavior. Biol Psychiatry. 1989 Feb 1;25(3):265-74. doi: 10.1016/0006-3223(89)90174-1."},{"pmid":"6367973","type":"BACKGROUND","citation":"Nutt JG, Fellman JH. Pharmacokinetics of levodopa. Clin Neuropharmacol. 1984;7(1):35-49. doi: 10.1097/00002826-198403000-00002. No abstract available."},{"pmid":"19520987","type":"DERIVED","citation":"Cramer SC, Dobkin BH, Noser EA, Rodriguez RW, Enney LA. Randomized, placebo-controlled, double-blind study of ropinirole in chronic stroke. Stroke. 2009 Sep;40(9):3034-8. doi: 10.1161/STROKEAHA.109.552075. Epub 2009 Jun 11."}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000010291","term":"Paresis"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000009461","term":"Neurologic Manifestations"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Cerebrovascular Accident","relevance":"HIGH"},{"id":"M20634","name":"Muscle Weakness","relevance":"LOW"},{"id":"M12894","name":"Paresis","asFound":"Hemiparesis","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M12094","name":"Neurologic Manifestations","relevance":"LOW"},{"id":"T1303","name":"Chronic Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC05","name":"Musculoskeletal Diseases"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C000046649","term":"Ropinirole"}],"ancestors":[{"id":"D000000978","term":"Antiparkinson Agents"},{"id":"D000018726","term":"Anti-Dyskinesia Agents"},{"id":"D000018491","term":"Dopamine Agonists"},{"id":"D000015259","term":"Dopamine Agents"},{"id":"D000018377","term":"Neurotransmitter Agents"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000045505","term":"Physiological Effects of Drugs"}],"browseLeaves":[{"id":"M224656","name":"Ropinirole","asFound":"Transurethral","relevance":"HIGH"},{"id":"M3985","name":"Antiparkinson Agents","relevance":"LOW"},{"id":"M7163","name":"Dopamine","relevance":"LOW"},{"id":"M20285","name":"Dopamine Agonists","relevance":"LOW"},{"id":"M17652","name":"Dopamine Agents","relevance":"LOW"},{"id":"M20194","name":"Neurotransmitter Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"AnDyAg","name":"Anti-Dyskinesia Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"CaAg","name":"Cardiotonic Agents"}]}},"hasResults":false}